Adalimumab in Adult Japanese Subjects With Psoriasis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

147

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

September 30, 2007

Study Completion Date

April 30, 2010

Conditions
Psoriasis
Interventions
BIOLOGICAL

adalimumab

Adalimumab 40 mg every other week, subcutaneous

BIOLOGICAL

adalimumab

Adalimumab 80 mg every other week, subcutaneous

Trial Locations (64)

Unknown

Site Ref # / Investigator 5491, Bunkyō City

Site Ref # / Investigator 5429, Chiyoda-ku

Site Ref # / Investigator 5464, Fukuoka

Site Ref # / Investigator 5477, Fukuoka

Site Ref # / Investigator 5492, Fukuoka

Site Ref # / Investigator 5504, Fukuoka

Site Ref # / Investigator 5400, Fukushima

Site Ref # / Investigator 5406, Fukushima

Site Ref # / Investigator 5407, Fukushima

Site Ref # / Investigator 5437, Fukushima

Site Ref # / Investigator 5401, Gifu

Site Ref # / Investigator 5434, Gifu

Site Ref # / Investigator 5408, Hamamatsu

Site Ref # / Investigator 5495, Hiroshima

Site Ref # / Investigator 5391, Hokkaido

Site Ref # / Investigator 5402, Ishikawa

Site Ref # / Investigator 5431, Itabashi-ku

Site Ref # / Investigator 5462, Kagoshima

Site Ref # / Investigator 5476, Kagoshima

Site Ref # / Investigator 5435, Kanagawa

Site Ref # / Investigator 5432, Kawachi-gun

Site Ref # / Investigator 5440, Kawasaki

Site Ref # / Investigator 5499, Kyoto

Site Ref # / Investigator 5503, Kyoto

Site Ref # / Investigator 5411, Minatoku

Site Ref # / Investigator 5404, Mitaka

Site Ref # / Investigator 5417, Miyagi

Site Ref # / Investigator 5463, Nagasaki

Site Ref # / Investigator 5427, Nagoya

Site Ref # / Investigator 5465, Nankoku

Site Ref # / Investigator 5493, Nankoku

Site Ref # / Investigator 5482, Nishinomiya

Site Ref # / Investigator 5395, Numakunai

Site Ref # / Investigator 5496, Okayama

Site Ref # / Investigator 5441, Osaka

Site Ref # / Investigator 5467, Osaka

Site Ref # / Investigator 5480, Osaka

Site Ref # / Investigator 5483, Osaka

Site Ref # / Investigator 5498, Osaka

Site Ref # / Investigator 5388, Sapporo

Site Ref # / Investigator 5396, Sapporo

Site Ref # / Investigator 5399, Sapporo

Site Ref # / Investigator 5414, Shinjuku-ku

Site Ref # / Investigator 5433, Shizuoka

Site Ref # / Investigator 5466, Suita

Site Ref # / Investigator 5497, Suita

Site Ref # / Investigator 5505, Suita

Site Ref # / Investigator 5481, Tokushima

Site Ref # / Investigator 5506, Tokushima

Site Ref # / Investigator 6918, Tokushima

Site Ref # / Investigator 5405, Tokyo

Site Ref # / Investigator 5409, Tokyo

Site Ref # / Investigator 5410, Tokyo

Site Ref # / Investigator 5412, Tokyo

Site Ref # / Investigator 5413, Tokyo

Site Ref # / Investigator 5430, Tokyo

Site Ref # / Investigator 6553, Tokyo

Site Ref # / Investigator 5468, Tsu

Site Ref # / Investigator 5475, Ube

Site Ref # / Investigator 5415, Urayasu

Site Ref # / Investigator 5438, Urayasu

Site Ref # / Investigator 5416, Yamagata

Site Ref # / Investigator 5403, Yokohama

Site Ref # / Investigator 5428, Yokohama

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Abbott Japan Co.,Ltd

INDUSTRY

collaborator

Eisai Co., Ltd.

INDUSTRY

lead

Abbott

INDUSTRY

NCT00647400 - Adalimumab in Adult Japanese Subjects With Psoriasis | Biotech Hunter | Biotech Hunter